NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells

Hassane M. Zarour, Bernard Maillere, Vladimir Brusic, Kara Coval, Eileen Williams, Sandra Pouvelle-Moratille, Florence Castelli, Stephanie Land, Jaafar Bennouna, Theodore Logan, Theodore Logan

Research output: Contribution to journalArticle

106 Citations (Scopus)

Abstract

The NY-ESO-1 gene product is expressed by a range of human tumors and is recognized by antibodies from sera of cancer patients with NY-ESO-1-expressing tumors. The NY-ESO-1 gene also encodes several MHC class I- and MHC class II-restricted tumor epitopes recognized by T lymphocytes. In particular, we previously reported that the NY-ESO-1 119-143 peptide contains at least two HLA-DRB1*0401-presented epitopes that are recognized by melanoma-reactive CD4+ T cells. Here we report that the NY-ESO-1 119-143 peptide can be presented in the context of multiple HLA-DR alleles to stimulate tumor-reactive CD4+ T cells. The NY-ESO-1 119-143 peptide is able to bind to several DR molecules. The NY-ESO-1 119-143 peptide is also capable of inducing specific CD4+ T cells in vitro from peripheral blood lymphocytes of normal donors and patients with melanoma who express these HLA-DR alleles. These CD4+ T cells recognize NY-ESO-1+, HLA-matched or autologous melanoma cell lines, as well as autologous antigen-presenting cells fed with the NY-ESO-1 protein. We also demonstrate that the NY-ESO-1 119-143 peptide stimulates in vitro both Th1-type and Th2-type CD4+ T-cell responses from peripheral blood lymphocytes of normal donors and melanoma patients. Taken together, these data suggest a key role of the NY-ESO-1 119-143 peptide sequence in the induction of cellular and humoral responses against NY-ESO-1-expressing tumors. They support the relevance of cancer vaccine trials with the NY-ESO-1 119-143 peptide in the large number of cancer patients with NY-ESO-1-expressing tumors.

Original languageEnglish (US)
Pages (from-to)213-218
Number of pages6
JournalCancer Research
Volume62
Issue number1
StatePublished - Jan 1 2002
Externally publishedYes

Fingerprint

Major Histocompatibility Complex
Epitopes
T-Lymphocytes
Peptides
Melanoma
Neoplasms
HLA-DR Antigens
Alleles
Tissue Donors
Lymphocytes
Cancer Vaccines
T-Lymphocyte Epitopes
Autoantigens
Antigen-Presenting Cells
Genes
Cell Line
Antibodies
Serum
Proteins

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells. / Zarour, Hassane M.; Maillere, Bernard; Brusic, Vladimir; Coval, Kara; Williams, Eileen; Pouvelle-Moratille, Sandra; Castelli, Florence; Land, Stephanie; Bennouna, Jaafar; Logan, Theodore; Logan, Theodore.

In: Cancer Research, Vol. 62, No. 1, 01.01.2002, p. 213-218.

Research output: Contribution to journalArticle

Zarour, HM, Maillere, B, Brusic, V, Coval, K, Williams, E, Pouvelle-Moratille, S, Castelli, F, Land, S, Bennouna, J, Logan, T & Logan, T 2002, 'NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells', Cancer Research, vol. 62, no. 1, pp. 213-218.
Zarour, Hassane M. ; Maillere, Bernard ; Brusic, Vladimir ; Coval, Kara ; Williams, Eileen ; Pouvelle-Moratille, Sandra ; Castelli, Florence ; Land, Stephanie ; Bennouna, Jaafar ; Logan, Theodore ; Logan, Theodore. / NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells. In: Cancer Research. 2002 ; Vol. 62, No. 1. pp. 213-218.
@article{f0e8864f81f344fab3238ef173c209d8,
title = "NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells",
abstract = "The NY-ESO-1 gene product is expressed by a range of human tumors and is recognized by antibodies from sera of cancer patients with NY-ESO-1-expressing tumors. The NY-ESO-1 gene also encodes several MHC class I- and MHC class II-restricted tumor epitopes recognized by T lymphocytes. In particular, we previously reported that the NY-ESO-1 119-143 peptide contains at least two HLA-DRB1*0401-presented epitopes that are recognized by melanoma-reactive CD4+ T cells. Here we report that the NY-ESO-1 119-143 peptide can be presented in the context of multiple HLA-DR alleles to stimulate tumor-reactive CD4+ T cells. The NY-ESO-1 119-143 peptide is able to bind to several DR molecules. The NY-ESO-1 119-143 peptide is also capable of inducing specific CD4+ T cells in vitro from peripheral blood lymphocytes of normal donors and patients with melanoma who express these HLA-DR alleles. These CD4+ T cells recognize NY-ESO-1+, HLA-matched or autologous melanoma cell lines, as well as autologous antigen-presenting cells fed with the NY-ESO-1 protein. We also demonstrate that the NY-ESO-1 119-143 peptide stimulates in vitro both Th1-type and Th2-type CD4+ T-cell responses from peripheral blood lymphocytes of normal donors and melanoma patients. Taken together, these data suggest a key role of the NY-ESO-1 119-143 peptide sequence in the induction of cellular and humoral responses against NY-ESO-1-expressing tumors. They support the relevance of cancer vaccine trials with the NY-ESO-1 119-143 peptide in the large number of cancer patients with NY-ESO-1-expressing tumors.",
author = "Zarour, {Hassane M.} and Bernard Maillere and Vladimir Brusic and Kara Coval and Eileen Williams and Sandra Pouvelle-Moratille and Florence Castelli and Stephanie Land and Jaafar Bennouna and Theodore Logan and Theodore Logan",
year = "2002",
month = "1",
day = "1",
language = "English (US)",
volume = "62",
pages = "213--218",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "1",

}

TY - JOUR

T1 - NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells

AU - Zarour, Hassane M.

AU - Maillere, Bernard

AU - Brusic, Vladimir

AU - Coval, Kara

AU - Williams, Eileen

AU - Pouvelle-Moratille, Sandra

AU - Castelli, Florence

AU - Land, Stephanie

AU - Bennouna, Jaafar

AU - Logan, Theodore

AU - Logan, Theodore

PY - 2002/1/1

Y1 - 2002/1/1

N2 - The NY-ESO-1 gene product is expressed by a range of human tumors and is recognized by antibodies from sera of cancer patients with NY-ESO-1-expressing tumors. The NY-ESO-1 gene also encodes several MHC class I- and MHC class II-restricted tumor epitopes recognized by T lymphocytes. In particular, we previously reported that the NY-ESO-1 119-143 peptide contains at least two HLA-DRB1*0401-presented epitopes that are recognized by melanoma-reactive CD4+ T cells. Here we report that the NY-ESO-1 119-143 peptide can be presented in the context of multiple HLA-DR alleles to stimulate tumor-reactive CD4+ T cells. The NY-ESO-1 119-143 peptide is able to bind to several DR molecules. The NY-ESO-1 119-143 peptide is also capable of inducing specific CD4+ T cells in vitro from peripheral blood lymphocytes of normal donors and patients with melanoma who express these HLA-DR alleles. These CD4+ T cells recognize NY-ESO-1+, HLA-matched or autologous melanoma cell lines, as well as autologous antigen-presenting cells fed with the NY-ESO-1 protein. We also demonstrate that the NY-ESO-1 119-143 peptide stimulates in vitro both Th1-type and Th2-type CD4+ T-cell responses from peripheral blood lymphocytes of normal donors and melanoma patients. Taken together, these data suggest a key role of the NY-ESO-1 119-143 peptide sequence in the induction of cellular and humoral responses against NY-ESO-1-expressing tumors. They support the relevance of cancer vaccine trials with the NY-ESO-1 119-143 peptide in the large number of cancer patients with NY-ESO-1-expressing tumors.

AB - The NY-ESO-1 gene product is expressed by a range of human tumors and is recognized by antibodies from sera of cancer patients with NY-ESO-1-expressing tumors. The NY-ESO-1 gene also encodes several MHC class I- and MHC class II-restricted tumor epitopes recognized by T lymphocytes. In particular, we previously reported that the NY-ESO-1 119-143 peptide contains at least two HLA-DRB1*0401-presented epitopes that are recognized by melanoma-reactive CD4+ T cells. Here we report that the NY-ESO-1 119-143 peptide can be presented in the context of multiple HLA-DR alleles to stimulate tumor-reactive CD4+ T cells. The NY-ESO-1 119-143 peptide is able to bind to several DR molecules. The NY-ESO-1 119-143 peptide is also capable of inducing specific CD4+ T cells in vitro from peripheral blood lymphocytes of normal donors and patients with melanoma who express these HLA-DR alleles. These CD4+ T cells recognize NY-ESO-1+, HLA-matched or autologous melanoma cell lines, as well as autologous antigen-presenting cells fed with the NY-ESO-1 protein. We also demonstrate that the NY-ESO-1 119-143 peptide stimulates in vitro both Th1-type and Th2-type CD4+ T-cell responses from peripheral blood lymphocytes of normal donors and melanoma patients. Taken together, these data suggest a key role of the NY-ESO-1 119-143 peptide sequence in the induction of cellular and humoral responses against NY-ESO-1-expressing tumors. They support the relevance of cancer vaccine trials with the NY-ESO-1 119-143 peptide in the large number of cancer patients with NY-ESO-1-expressing tumors.

UR - http://www.scopus.com/inward/record.url?scp=0036141435&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036141435&partnerID=8YFLogxK

M3 - Article

C2 - 11782380

AN - SCOPUS:0036141435

VL - 62

SP - 213

EP - 218

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 1

ER -